pashtun

VSAR - Long Opportunity

NASDAQ:VSAR   None
Versartis Inc, had a clinical trial that failed, same deal with AXON and few others, but they still have 3 or 4 trials pending. Dont think it would fall lower. If they have trials left but not that good at these kind of plays. Keep an eye on this one forsure. Might just hold a small lot, 52 week high was 24 $.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.